Literature DB >> 35073168

Precision Medicine in Low- and Middle-Income Countries.

Jerald P Radich1,2,3, Edward Briercheck1,2, Daniel T Chiu4, Manoj P Menon1,2,3,5, Olga Sala Torra2, Cecilia C S Yeung2,3, Edus H Warren1,2,3,5.   

Abstract

Most cancer cases occur in low- and middle-income countries (LMICs). The sophisticated technical and human infrastructure needed for optimal diagnosis, treatment, and monitoring of cancers is difficult enough in affluent countries; it is especially challenging in LMICs. In Western, educated, industrial, rich, democratic countries, there is a growing emphasis on and success with precision medicine, whereby targeted therapy is directed at cancers based on the specific genetic lesions in the cancer. Can such precision approaches be delivered in LMICs? We offer some examples of novel partnerships and creative solutions that suggest that precision medicine may be possible in LMICs given heavy doses of will, creativity, and persistence and a little luck.

Entities:  

Keywords:  LMICs; diagnostics; precision medicine

Mesh:

Year:  2022        PMID: 35073168      PMCID: PMC9275191          DOI: 10.1146/annurev-pathol-042320-034052

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   32.350


  60 in total

1.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

2.  Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots.

Authors:  Olga Sala Torra; Lan Beppu; Jordan L Smith; Linda Welden; Jasmina Georgievski; Karisma Gupta; Rashmi Kumar; Cecilia C S Yeung; Amy Paguirigan; Ted A Gooley; Susan Branford; Jerald P Radich
Journal:  Blood       Date:  2016-04-13       Impact factor: 22.113

3.  Evaluation of the Cepheid GeneXpert BCR-ABL assay.

Authors:  Zsolt Jobbagy; Reuel van Atta; Kathleen M Murphy; James R Eshleman; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

4.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

5.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Authors:  David M Ross; Susan Branford; John F Seymour; Anthony P Schwarer; Christopher Arthur; David T Yeung; Phuong Dang; Jarrad M Goyne; Cassandra Slader; Robin J Filshie; Anthony K Mills; Junia V Melo; Deborah L White; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

6.  Development of an integrated assay for detection of BCR-ABL RNA.

Authors:  Emily S Winn-Deen; Bret Helton; Reuel Van Atta; Wendy Wong; Jeffrey Peralta; James Wang; Gregory J Tsongalis; Dorothy Belloni; David Chan; James R Eshleman; Christopher D Gocke; Zsolt Jobbagy; Lan Beppu; Jerald P Radich
Journal:  Clin Chem       Date:  2007-07-27       Impact factor: 8.327

Review 7.  BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.

Authors:  Martin H Luu; Richard D Press
Journal:  Expert Rev Mol Diagn       Date:  2013-09       Impact factor: 5.225

Review 8.  Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge.

Authors:  Yehoda M Martei; Lydia E Pace; Jane E Brock; Lawrence N Shulman
Journal:  Clin Lab Med       Date:  2017-12-13       Impact factor: 1.935

9.  Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

Authors:  Susan Branford; David T Yeung; David M Ross; Jodi A Prime; Chani R Field; Haley K Altamura; Alexandra L Yeoman; Jasmina Georgievski; Bronte A Jamison; Stuart Phillis; Brad Sullivan; Nancy E Briggs; Mark Hertzberg; John F Seymour; John Reynolds; Timothy P Hughes
Journal:  Blood       Date:  2013-03-20       Impact factor: 22.113

10.  Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

Authors:  Dragana Milojkovic; Jane F Apperley; Gareth Gerrard; Amr R Ibrahim; Richard Szydlo; Marco Bua; Alistair Reid; Katayoun Rezvani; Letizia Foroni; John Goldman; David Marin
Journal:  Blood       Date:  2011-12-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.